This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

7 High-Volume Stocks With Relative Strength

Questcor Pharmaceuticals

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Questcor Pharmaceuticals (QCOR) is a biopharmaceutical company. Questcor's primary product is H.P. Acthar Gel (repository corticotropin injection) (Acthar), an injectable drug that is approved by the U.S. Food and Drug Administration, for the treatment of 19 indications. This stock is trading up 10.4% at $55.49 in recent trading.

Today's Volume: 4.5 million

Average Volume: 1.85 million

Volume % Change: 306%

Shares of QCOR are skyrocketing today after the company reported strong second-quarter sales of its flagship multiple sclerosis drug Acthar. The company shipped 4,710 vials of Acthar for Apirl to June, which represented a 15% rise from the previous quarter.

>>22 Biopharma Stocks With Breakout Potential in 2012

From a technical perspective, QCOR is gapping up huge with monster volume. This gap-up has pushed QCOR into breakout territory, since the stock has moved above some near-term overhead resistance at $54.31. At last check, QCOR has hit an intraday high of $58.91 and the volume is well above its three-month average action of 1.85 million shares. Amazingly, this move has yet to push QCOR into extremely overbought territory since its current relative strength index reading is just 69.25.

Traders should now look for long-biased trades once QCOR breaks out above today's high of $58.91 with strong volume. Look for a sustained move or close above $58.91 with volume that's near or above 1.85 million shares. Traders can also look for long-trades as long as QCOR is trending above that key breakout point of $54.31.

Questcor shows up on a list of Hot Biotech Stocks Traded by Hedge Funds in the most recently reported quarter.
3 of 8

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
AKRX $43.32 -0.78%
QCOR $93.60 1.65%
OSUR $5.37 -0.37%
OSIR $19.56 0.51%
SYNC $1.61 0.00%

Markets

DOW 17,757.91 +138.40 0.79%
S&P 500 2,077.42 +14.31 0.69%
NASDAQ 5,013.1230 +26.2560 0.53%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs